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High blood concentrations of low-density lipoproteins (LDL) and low blood concentrations of high-density lipoproteins (HDL) are primary factors for the development of atherosclerotic disease, the leading cause of death in industrialized countries. A decrease of approximately 30% in the morbidity-mortality rate of the disease is attributed to the reduction of LDL-C (cholesterol linked to LDL) by the statins. To improve this rate, the focus has shifted to possibilities of increasing HDL-C (cholesterol linked to HDL), the cholesterol fraction considered protective and anti-risk factor.
In this article, we address aspects of HDL metabolism and function, conditions that affect its blood levels, its role in atherosclerotic disease, as well as current and developing therapeutic approaches aimed to increasing its levels.
METABOLIC ASPECTS Identification
Lipoproteins (LP) consist of lipids and proteins called apoproteins (apo). They are classified according to size, density, and lipid and apoprotein composition: chylomicrons (CHY), very low-density lipoprotein (VLDL), intermediatedensity lipoproteins (IDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL).
HDL particles consist of 50% apoproteins (AI in larger quantity, AII, CI, CII, CIII, E, and J), 20% of free cholesterol (FC) and esterified (CE) cholesterol, 15% of phospholipids (PL), and 5% of triglycerides (TG) (Fig. 1 ). They are identified by lipoprotein separation using ultracentrifugation, electrophoresis, and nuclear magnetic resonance. In ultracentrifugation, HDL particles are separated at densities that range from 1.063 to 1.210, further separating into subfractions: HDL 2 at densities 1.063 to 1.125, and HDL 3 at densities 1.125 to 1.210. VHDL particles are found between densities 1.121 to 1.125. By electrophoresis, 90% to 95% of the HDL particles, i.e., virtually all those that contain more apoA-I, also known as LpA-I, present alpha mobility, and only 5% to 10% have beta mobility. By non-denaturating polyacrylamide gel electrophoresis, HDL particles, previously separated by ultracentrifugation, are classified into 5 subfractions by decreasing order of size: HDL 2b , HDL 2a , HDL 3a , HDL 3b and HDL 3c. Nuclear magnetic resonance provides separation into 5 classes of subparticles: H5, H4 and H3, the largest, correspond to HDL 2 , and H2, H1 correspond to HDL 3 . In clinical laboratory, HDL particles are indirectly determined by the cholesterol associated with them (HDL-C) [1] [2] [3] [4] [5] [6] . According to contents of apoA-I and apoA-II, they are called LpA-I (most of them have the same density and HDL 2 load) and LpA-I + AII (most of them have the same HDL 3 density and load) 5 .
HDL Formation
HDL particles are formed in plasma and in the extravascular space 7 . In order to better understand this process, it is first of all necessary to be acquainted with the secretion of the main apolipoprotein components and cholesterol efflux from peripheral cells.
The liver secretes A-I and A-II apolipoproteins, whereas the intestine only secretes A-I. Free cholesterol present in peripheral cells generates oxysterols that are endogenous ligands for nuclear liver receptors (LXR) and retinoid receptors (RXR). These are also affected by the peroxisome proliferatoractivated receptors (PPARs) alpha and gamma. The LXR/RXR receptors and the cholesterol-regulating protein (SREBP) control the transcription of the cholesterol-transporter carrier gene (ABCAI) existing on the surface of macrophages in the artery wall. The ABCAI transporter promotes the exit of free cholesterol from the cell, which will be captured by apoA-I by the influence of the plasma phospholipid transfer protein (PLTP). There are also the ABCG1 transporters, expressed in macrophages and in endothelial cells, and the ABCG4 which is expressed in the brain. These transporters also promote cholesterol efflux 1, 3, 5, [8] [9] [10] [11] [12] [13] . Apolipoprotein A-I (apo A-I) participate in HDL formation through 3 pathways (Fig. 2) 3 : 1) capturing free cholesterol and phospholipids from peripheral cells, and forming pre-beta HDL. Influenced by lecithin-cholesterol acyltransferase (LCAT), free cholesterol is esterified, forming the round, mature, esterified-cholesterol-rich HDL particles. Still by influence of LCAT, the "mature" HDL particles are converted into HDL 3 particles (denser, even richer in esterified cholesterol), and later, also by PLTP action, acquire phospholipids and are converted into HDL 2 (less dense). It is worth mentioning that the interconversion between HDL 2 and HDL 3 takes place in arterial wall and in plasma ( Fig. 3 ; 2) discoid particles containing apoA-I, phospholipids and free cholesterol are secreted by liver and intestine and are transformed, by the action of the LCAT enzyme, into mature HDL particles; 3) TG-rich lipoproteins (CHY, IDL, VLDL) undergo lipoprotein lipase (LLP) action, releasing fragments containing phospholipids, free cholesterol, and small apoproteins. These fragments go into the HDL pool.
Reverse Cholesterol Transport
After being formed, HDL particles are captured by liver via the SRB1 receptors (Scavenger receptor B, class 1) and apoE receptors 8, 14, 15 (also present in adrenal glands and ovaries), that selectively remove esterified cholesterol from liver. Hepatic cholesterol is then excreted in bile, mediated by ABCG5/ ABCG8 transporters 7, 11, 14 . Additionally, there is exchange of cholesterol linked to HDL with TG of VLDL, IDL, and LDL, and this exchange is mediated by CETP whose expression is regulated by SREBP and LXR/RXR. Therefore, HDL becomes richer in TG, and cholesterol bound to LDL, IDL, and LDL is captured by B/E hepatic receptors 1, 5 .
The reverse cholesterol transport, therefore, consist of two pathways: 1) 50% directly, by the uptake of HDL-free cholesterol involving SRB1; 2) 50% indirectly, involving CETP 1 .
Catabolism
Hepatic lipase (HL) acts on TG-rich HDL particles hydrolyzing phospholipids and TG, and facilitating interaction with SRB1 receptors. HDLs then return to the interstitium proportionally with more and smaller proteins, reinitiating the cholesterol removal cycle 1 . Some authors consider that apoA-I is broken down via SRB1, while others believe that apoA-1 and/or TG-rich HDLs are catabolized in the kidneys by endocytosis in proximal tube with participation of cubilinmegalin proteic complex 1, 5, 7, 16, 17 .
HDL Actions
Several different actions are attributed to HDLs, which taken all together, have an anti-atherogenic effect. The primary action is the reverse cholesterol transport, mentioned above. Other actions have been described in vitro and in animals, such as: antioxidant, anti-inflammatory, platelet antiaggregant, anticoagulant, profibrinolytic, and endothelial protection effects 2, 3, 5, 8, 18 . HDL particles contain the paraoxonase enzyme that is capable of hydrolyzing lipid peroxides by catalyzing the reaction of oxidized phospholipids into LDL 5, 19 . They eliminate the products of LDL oxidation (lipoperoxides and lysophosphatidylcholine) 3, 20 . Anticoagulant and profibrinolytic Low HDL levels are clinical findings commonly associated with smoking (due to LCAT deficiency), visceral obesity (due to decreased LCAT and LLP), very low-fat diets, hypertriglyceridemia, and use of certain drugs (such as beta-adrenergic blocking agents, steroids, and androgenic progestogens) [42] [43] [44] [45] .
Elevated HDL Levels
High HDL levels are rarely associated to genetic disorders, such as CETP or HL deficiency. In CEPT deficiency, HDL is very rich in esterified cholesterol, although there is no evidence that it has a protective effect against atherosclerosis 13 .
They are generally associated with the regular practice of aerobic exercises (by increasing LCAT and LLP, and reducing HL), diets rich in saturated fat and cholesterol (by delaying apoA-I clearance), regular alcohol consumption (by inhibiting HL and increasing apoA-I and apoA-II synthesis), and use of some medications such as estrogens (by increasing apoA-I production and inhibiting HL) and phenytoin 42, [46] [47] [48] [49] [50] .
HDL Role in the Atherosclerotic Disease
Experimental, epidemiologic, clinical, and therapeutic intervention investigations have shown that there is an inverse relationship between HDL-C and atherosclerotic disease. To date, there are no reports of anatomical and pathological studies conducted on human subjects or animals showing the direct association of HDL and lesion progression. HDL atherogenicity may be influenced by non-measurable variables, including genetic and acquired factors, or by subclass concentration, metabolic kinetics, and not by absolute quantities of HDL 5, 51, 52 . Studies conducted with different populations showed that risk for CAD, if HDL-C is low, is accompanied by other lipid alterations, such as hypertriglyceridemia (specially if the TC/HDL-C is high), an increased concentration of remnant lipoproteins, and small and dense LDL particles. These alterations may be associated with the metabolic syndrome 5, [53] [54] [55] [56] [57] .
Experimental Studies
ApoA-I administration to transgenic mice delays formation of atherosclerotic lesions 7, 58 . In rabbits, injection of HDL-VHDL promoted the regression of fatty streak and lipid deposits caused by diets very rich in cholesterol. Injection of apoA-I in hyperlipidemic rabbits lead to reduction in intima thickness and in contents of macrophage cells after balloon injury 18, [59] [60] [61] . In rats with apo-E deficiency, administration of apoA-I was associated to increase of HDL-C (2 to 3x) and lower susceptibility (6x) to atherosclerosis, and also reduced neointimal formation after endothelial denudation 18, 62, 63 .
Epidemiological studies
Several epidemiological studies have shown that there is an inverse relationship between HDL-C blood levels and the effects are based on inhibition of X-factor and platelet activation, tPA secretion (tissue plasminogen activator), and PAI (plasminogen activator inhibitor) 2, 3, 5, 21 . They stimulate Creactive protein activity 2 .
Endothelial protection takes place by: 1) inhibition of oxidized LDL infiltration and consequent protection against acetylcholine-mediated vasodilation and antagonism of vasodilation inhibition caused by lysophosphatidylcholine 20 ; 2) inhibition of adhesion of monocytes to the endothelium by inhibiting adhesion molecules to be expressed on the endothelial surface: VCAM1 (vascular cell adhesion molecule), ICAM1 (intracellular adhesion molecule), and E-selectin. Interleukins 1 (IL1) and 8 (IL8) are also reduced. The HDL 2 particles, in particular, can completely eliminate the adhesion of monocytes to endothelial cells 22 ; 3) smaller production of endothelin-1 by the endothelial cells 23 ; 4) stimulation of prostacyclin synthesis and longer half-life, improving muscle relaxation 24 ; 5) modulation of C-type natriuretic peptide production, which causes vasodilation 25 ; 6) activation of eNOS (endothelial nitric oxide synthesis), releasing NO 26, 27 ; 7) stimulation of smooth muscle cell production, which may facilitate the recovery of cells lost after the rupture of the atherosclerotic lesion fibrous cap 2,28 ; 8) prevention of cell injury and necrosis resulting from activation of the complement system 29 .
HDL Levels
Based on epidemiologic studies, HDL-C levels < 35 mg/dl are considered low for men, and < 45 mg/dl low for women 30, 31 . Updated guidelines established that values < 40 mg/dl are undesirable and increase risk for coronary atherosclerotic disease (CAD), whereas values > 60 mg/dl are "protective" [32] [33] [34] . To characterize the metabolic syndrome, along with other abnormalities, HDL-C values < 40 mg/dl are established for men, < 50 mg/dl for women 32, 33 . In recent publication, values < 50 mg/dl were established as risk for women.
Low or high HDL values result from rare genetic causes or are associated with other risk factors and/or medications.
Low HDL Levels
Genetic causes for low levels of HDL include: 1) total deficiency or mutations of apolipoprotein A-I. ApoA-I Milano and apoA-I Paris are mutations in which cysteine is replaced by arginine at locus 173 and 151, respectively. Despite low levels of HDL-c, patients with these mutations have no atherosclerotic involvement. In experiments, these variants were found to be more effective than the original apoA-I in preventing lipid oxidation, and they are also capable of mediating cholesterol efflux from macrophage cells by interacting with ABCAI 36-38 ; 2) complete or partial LCAT deficiency. Fish-eye disease is one form of latter in which patients exhibit low HDL and apoA-I levels, accelerated apoA-I and apo-AII catabolism, remarkable lipid corneal arc, but rarely develop premature atherosclerosis 39 ; 3) genetic disorders related to the ABCAI carrier, such as Tangier disease and familial hypoalphalipoproteinemia. In Tangier disease, HDL levels are extremely low, as are those of apoA-I and 5, 11, 18 . We call attention for: 1) World Health Organization study 64 , analysed data from 19 countries and showed an inverse correlation between HDL-C values and mortality due to CAD; 2) Framingham study 65 , in which an inverse correlation between HDL-C levels and CAD was observed in men and women of different age groups, and also that the risk is greater with HDL-C are < 40 mg/dl, regardless of LDL-C values. HDL-C > 65 mg/dL conferred protection against coronary events, even if LDL-c >160 mg/dl. The relationship was maintained after other risk factors had been controlled, such as diabetes mellitus, hyperglycemia, age, arterial hypertension, smoking, and obesity; 3) Prospective Cardiovascular Munster Study (PROCAM) 54 , in which men with HDL-C < 35 mg/dL had a greater risk for CAD relative to those with HDL-C > 35 mg/dL; 4) control groups of the Multiple Risk Factor Intervention Trial (MRFIT) 66 and of the Lipids Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) 67 , in which the incidence of CAD was greater at HDL-C levels < 40 mg/dL; 5) Lipid Research Clinics Prevalence Mortality Follow-up Study 68 shows an increase of 1 mg/dL in HDL-C associated to a 3.5% reduction in the risk for CAD, a mortality rate of 3.7% in men and 4.7% in women for HDL-C < 35 mg/dL, and the risk for cardiovascular disease (CVD) 6 times higher if HDL-C < 35 mg/dL.
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Combined analysis of the Framingham, Lipid Research
Clinics Prevalence Mortality Follow-up Study, and the LRC-CPPT and MRFIT control groups revealed that, after the adjustment for other risk factors, for each 1 mg/dl reduction in HDL-C, the risk for CAD increases 3% in women and 2% in men 69 .
It is worth mentioning that elevated HDL-C levels do not necessarily confer protection against atherosclerotic disease and, sometimes, are associated to an excessive cardiovascular risk. This situation was observed in PROCAM and Copenhagen City Heart studies in hypertriglyceridemic patients. In PROCAM and in a Belgium population sample, there was excessive mortality in the 5 th quintile of HDL-C in comparison with intermediate levels 4, 54, [70] [71] [72] .
Clinical and therapeutic intervention studies
The inverse relationship between HDL-C blood concentrations and atherosclerotic lesions in coronary arteries has been demonstrated by several clinical and therapeutic intervention studies.
Atherosclerotic impairment and lipid deposits in different organs were observed in individuals with low levels of HDL-C of unknown etiology. In clinical setting, coronary artery injuries are linked to low levels of HDL-C associated to smoking, obesity, hypertriglyceridemia, and metabolic syndrome.
Drexel et al 73 observed that the number of coronary atherosclerotic lesions was inversely proportional to HDL 2 values, and this fraction is a better "predictor" of lesion extension. In a study conducted in 80 males with coronary disease, aged 27 to 55 years, smokers, sedentary, non-diabetic and non-obese, Giannini et al 74 had been found when the injury was more pronounced. Shah and Amin 75 , in a study conducted with patients who had undergone coronary angioplasty, observed that low HDL-C levels can be considered "predictive" of intimal proliferation, which leads to early restenosis.
Recently, Kuvin et al 76 showed that in coronary disease patients, the endothelium-mediated vasodilation was: 1) greater if LDL-C values were < 80 mg/dl, in comparison with HDL-C ≥ 80 mg/dL and < 100 mg/dL, but this difference was significant only when HDL-C were < 40 mg/dL; 2) greater in individuals with LDL-C < 75 mg/dL and HDL-C ≤ 36 mg/dL treated with niacin in comparison with no treated.
Studies of therapeutic intervention in patients with hyperlipidemia or in individuals with low blood concentrations of HDL-C showed, as explained below, that increase in HDL-C values is associated to a decrease in mortality and risks of new coronary events, as well possibility of lesion regression 5, 18, 46, [76] [77] [78] .
Therapeutic measures to increase HDL-C
With regard to measures used to reduce morbidity-mortality due to CAD, over the past few years the focus has been shifted to those capable of increasing blood HDL-C concentrations, by changes in lifestyle or medication.
Lifestyle measures
Lifestyle measures include an adequate diet, physical exercise, smoking cessation, and lowering body weight for individuals who are overweight or obese.
Dietary habits
Specific diets intended to modify HDL-C levels require not only medical orientation, but also and attendance by a nutritionist 8, 46, 79 : 1) Saturated fatty acids raise HDL-C levels by delaying apoA-I clearance. Restriction of saturated fatty acids reduces TC and LDL-C, as well as HDL-C, and the latter is effective especially in women [80] [81] [82] [83] ; 2) omega 3 polyunsaturated fatty acids inhibit the hepatic secretion of VLDL and, thus, increase HDL-C. Omega 6 fatty acids reduce these levels by reducing apoA-I production and by increasing HDL catabolism; 3) monounsaturated fatty acids induce HDL-C elevation by reducing VLDL secretion; 4) unsaturated fatty acids, in transform, enhance apoA-I catabolism and, thus, reduce HDL-C 84 ; 5) carbohydrates reduce HDL-C by increasing its catabolism as well as the secretion of VLDL. Recently, Aude et al 85 ; showed that reduced ingestion of simple carbohydrates and an increased ingestion of complex carbohydrates, associated to an increase of mono-unsaturated fatty acids, result in a less marked reduction of HDL-C in comparison with the Phase 1 diet recommended by NCEP 31 . Westman et al 86 , in contrast, showed that increased HDL-C levels, induced by carbohydrate restriction, accompanied body weight loss; 6) alcohol consumption increasing HDL-C by inhibiting hepatic lipase and increasing apoA-I and A-II synthesis. This increase is dose-dependent: in normal individuals, the consumption of half a bottle of wine per day (39 g of alcohol) after six weeks increased HDL-C by 7 mg/dl, whereas one beer per day
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Arq Bras Cardiol 2006; 87 : 614-622 (13,5 g of alcohol) caused an increase of only 2 mg/dl 87, 88 ; 7) coffee reduces HDL-C by reducing LCAT and increasing CETP activities; 8) besides reducing lipid oxidation, cocoa polifenoles raise HDL-C by a mechanism not yet fully explained 89 .
Adoption of diet intended for lowering body weight is of greater importance. Caloric restriction increases HDL-C values. For each 3 kg of body weight lost, there is a corresponding 1 mg/dL elevation in HDL-C. Increase in LCAT and LLP activities is observed after a sustained six-week weight loss 42, 90, 91 . It should be emphasized that weight loss should be the main focus in metabolic syndrome, helping to control glycidic and lipidic disorders and arterial pressure 92 .
Smoking cessation
Smoking cessation increases LCAT activity and HDL-C concentrations return to previous levels within 30 to 60 days 44, 93 .
Improve physical exercise
Physical exercise increases LCAT and LLP activity and reduces HL 42, 47 activity, resulting in increased HDL levels: 1) in both normal individuals and those with different types of dyslipidemia (hypercholesterolemia, isolated hypertriglyceridemia or associated with low levels of HDL-C, isolated low HDL-C) 94, 95 ; 2) in obese and nonobese individuals 96 ; 3) particularly when associated to diet orientation. Compared to women, men have more significant HDL-C elevations when they adopt an adequate diet combined with physical exercises 97 ; 4) success depends on quantity and not on intensity of the exercise 98 .
Over the period of one year, the association of physical exercise with fat and cholesterol restriction raised HDL-C values by 2% and reduced those of LDL-C (8%) and TG (21%). In comparison to control group, there was greater regression (29% x 6%) and lower progression (10% x 45%) of coronary lesions 99 .
Drug Therapy

Hypolipidemic agents (lipid lowering drugs -lld) in clinical practice
Fibrates, nicotinic acid, and statins increase HDL-C 10%, 20%, and 5 to 10% respectively. Fibrates activate PPARs alpha in the liver, increasing apoA-I production; they also reduce the regulation of SRB1, lowering HDL clearance. Nicotinic acid reduces apoA-I catabolism. Statins reduce CETP activity and increase apoA-I synthesis; reduction in CETP mass has been observed with the use of atorvastatin and sinvastatin 5, 11, 77 . In a metanalysis of randomized studies conducted from 1966 to 2004 with fibrates and nicotinic acid, Birjmohum et al 100 showed that, despite a more marked elevation of HDL-C with nicotinic acid (16% x 10%), the decline in events was similar (27% x 25%). But this reduction was significantly associated to elevations in HDL-C levels induced by gemfibrozil in primary and secondary prevention studies 4, 5, 18 . In the Helsinki Heart Study -HHS 101 , elevations in HDL-C (10%) and reductions in LDL-C (10%) and TG (43%) were observed. Increases of HDL-C and the HDL-C/TC ratio were related to risk of CAD. In Veterans Affairs High-Density Lipoprotein Intervention Trial -VAHIT 102, 103 (mean initial value of HDL-C was equal to 32 mg/dL), after one year the 6% increase in HDL-C levels was accompanied by a 22% reduction in the death rates due to CAD or non-fatal MI. For each 5 mg/dL increase in HDL-C, the risk of coronary events fell by 11%. This did not occur in the Bezafibrate Infarction Prevention study 104, 105 in which HDL-C were high and increased 18%; the conclusion was that an increase in low HDL-C translates into greater protection.
In primary prevention studies (Air Force/Texas Coronary Atherosclerosis Prevention Study -AFCAPS/Tex CAPS) 106 and West of Scotland Prevastatin Study -WOS) 107 ), statins also reduced cardiovascular events, even more significantly so when HDL-C values were lower. However, this correlation was not significant 4 . In the AFCAPS study 106 , reductions were 45%, 44%, and 15% respectively if HDL-C was < 34, 35 to 39, or > 40 mg/dL. The combined analysis of WOS, CARE, and LIPID (Prospective Pravastatin Pooling Project 111 ) studies showed a similar reduction in cardiac events (27% to 28%) in both placebo and treatment groups, considering the more elevated HDL-C percentile in relation to the lowest 18 . In the 4S study, a 1% increase in HDL-C was associated with a 0.80% reduction in risk, regardless of the decline in LDL-C levels 112 . More distinct angiographic and clinical benefits were also observed in the Lipoprotein and Coronary Atherosclerosis Study -LCAS 5, 18, 113 . Combination of simvastatin and niacin, administered for 3 years, reduced the risk of events by 90% and each 1% increase in HDL-C corresponded to a 1% reduction in cardiovascular risk (HDL -Atherosclerosis Treatment Study -HATS) 5, 18, 114 . In 167 cardiac patients (x = 67 years of age) treated with statins, addition of niacin after 12 months, increased HDL-C (21%), but no modifications were observed in carotid intima-media thickness (increased in the placebo group) 115 . Whitney et al 115 recently published the results of an angiographic placebo-controlled study designed for individuals with low levels of HDL-C. After 6 months of a Phase 2 diet of the American Heart Association and regular physical exercises, patients (HDL-C = 34 ± 6 mg/dL, LDL-C = 128 ± 27 mg/dL, and TC = 196 ± 31 mg/dL), were randomized to receive placebo combined with gemfibrozil (1200 mg/dL), nicotinic acid (250 to 3000 mg/day from the 3 rd month) and cholestyramine (16 g/day from the 6 th month). Reductions in TC (20%), LDL-C (26%), and TG (50%), as well as an increase in HDL-C levels (36%) were observed. After 3 years, treated group had a greater reduction in coronary obstructive processes (↓ 0.8% x ↑ 1.4%) and in cardiovascular events (12.7% x 26.4%).
CETP inhibitors
Elevation of blood HDL-C levels is more pronounced due to the action of CETP inhibitors, drugs not yet available for clinical use 5, 11, 18 . Two of these are JTT-705 and torcetrapib. In rabbits, torcetrapib significantly reduced atherosclerosis 119 . In human subjects with HDL-C < 40 mg/dL (x = 33 mg/dL) receiving 120 mg/day, the drug increased HDL-C levels 46% after 4 weeks and 106% after 8 weeks. When associated to 20 mg/day of atorvastatin, after 4 weeks the increase was 61% 120 .
Drugs in development
Currently, there are studies underway with drugs capable of raising HDL-C by different mechanisms of action: PPARs alpha and gamma agonists, apoA-I synthesis inducers, selective LXR activators or modulators, FXR activators (farnesoid X receptor / biliary bile acid receptor), endothelial and hepatic lipase inhibitors, SRB1 modulators, and -mimetics of sphingolipids 11 .
Other possibilities
In an effort to increase HLD-C levels, CETP inhibition was induced in rabbits by a "vaccine" (a synthetic peptide homologous to the sequence of peptides in catalytic CETP site), which reduced the aortic lesions by 39.6% 121 . In human subjects, HDL-C increase was small 122 .
Infusion of apoA-I increases the ABCAI-mediated cholesterol efflux. In rabbits, repeated infusions of apoA-I inhibited the progression of atherosclerosis and reduced lesion size 123 . Recently, Nissen et al 124 showed that patients in acute phase of myocardial infarction had a reduction in atheroma volume due to endovenous administration of recombinant apoA-I Milano.
Summary
High density lipoproteins (HDL) constitute a class of heterogeneous lipoproteins with a complex, not fully understood metabolism, particularly concerning cholesteryl ester transfer protein (CETP) action and catabolism. HDLs are anti-atherogenic due to reverse cholesterol transport and to antioxidant, anti-inflammatory, anticoagulant, profibrinolytic and endothelial protection properties, (shown in vitro and in animals). Experimental, clinical, epidemiologic, and therapeutic intervention studies have shown that there is an inverse relationship between blood levels of these lipoproteins and the development of atherosclerotic disease in coronary arteries.
Measures to increase plasma HDL-C levels, besides changes in lifestyle habits (an adequate selection of diet components, smoking cessation, regular practice of aerobic exercises) include lipid lowering drugs (LLDs). Drugs capable of inhibiting CETP are currently in advanced stages of development. Research is also being conducted with other drugs that act on different points of lipid metabolism. 
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